Drugs / ACT500
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07589400 | May 2026 → Mar 2027 expected | chronic hepatitis B virus infection, metabolic dysfunction-associated steatotic liver disease | Xiamen Amoytop Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07462455 | Mar 2026 → Feb 2027 expected | metabolic dysfunction-associated steatohepatitis | Xiamen Amoytop Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06716905 | Mar → Sep 2025 | metabolic dysfunction-associated steatohepatitis | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07589400 ↗ |
| Known as | NM6606 | “A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Dose Escalations...” NCT06716905 ↗ |
| Route | Oral | “Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1” NCT06716905 ↗ |